News
RNA
24.62
-0.20%
-0.05
Weekly Report: what happened at RNA last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at RNA last week (0311-0315)?
Weekly Report · 03/18 10:45
Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge
Avidity Biosciences has a blockbuster product in deldesiran for myotonic dystrophy type 1 (DM1) Cantor Fitzgerald has initiated coverage on the company. The analyst says Avidity has accumulated extensive biomarker and clinical data. The company has a strong management team and a proven platform.
Benzinga · 03/14 19:29
Avidity Biosciences Initiated at Overweight by Cantor Fitzgerald
Dow Jones · 03/14 11:47
Avidity Biosciences Price Target Announced at $60.00/Share by Cantor Fitzgerald
Dow Jones · 03/14 11:47
Cantor Fitzgerald Initiates Coverage On Avidity Biosciences with Overweight Rating, Announces Price Target of $60
Benzinga · 03/14 11:37
Weekly Report: what happened at RNA last week (0304-0308)?
Weekly Report · 03/11 10:43
Avidity Biosciences: Strong Buy Rating Amidst Positive Clinical Developments and Price Target Surge
TipRanks · 03/07 04:25
Dyne: H2 2024 Muscle Disease Data Could Boost Value
Seeking Alpha · 03/05 19:48
Avidity Biosciences: Targeting A First Ever Approval In DM1 With Improving Data
Avidity Biosciences stock has gained more than 20% in the past five days due to positive long-term data for its lead candidate, AOC 1001, in DM1 patients. The company's market cap valuation is approximately $1.5 billion. Avidity has attracted major pharma companies for collaborations and licensing agreements. The drug is targeting approval in 2026 for its treatment of myotonic dystrophy type 1.
Seeking Alpha · 03/05 18:27
American Airlines To Rally Around 42%? Here Are 10 Top Analyst Forecasts For Tuesday
Barclays cut the price target for Noble Corporation plc from $61 to $59. Avadel Pharmaceuticals shares gained 17.6% to close at $16.13 on Monday. JP Morgan upgraded Sea Limited from Neutral to Overweight. The Chemours Company's price target was slashed from $37 to $21.
Benzinga · 03/05 14:30
A Closer Look at 5 Analyst Recommendations For Avidity Biosciences
Avidity Biosciences (NASDAQ:RNA) underwent analysis by 5 analysts in the last quarter. The biotechnology company has an average price target of $35.2. The company develops novel Antibody Oligonucleotide therapies to treat a range of serious diseases. The average 12-month price target has fallen from $36.50 to $23.00.
Benzinga · 03/05 12:00
Chardan Capital Maintains Buy on Avidity Biosciences, Raises Price Target to $33
Benzinga · 03/05 10:33
Avidity Biosciences Is Maintained at Buy by Chardan Capital
Dow Jones · 03/05 10:19
Avidity Biosciences Price Target Raised to $33.00/Share From $23.00 by Chardan Capital
Dow Jones · 03/05 10:19
Optimistic Buy Rating for Avidity Biosciences Backed by Promising Phase 3 Study Design and Positive MARINA OLE Data
Wells Fargo analyst Yanan Zhu assigned a Buy rating on Avidity Biosciences (RNA) yesterday and set a price target of $50.00. The company's product candidate AOC 1001, is designed to treat a rare monogenic muscle disease.
TipRanks · 03/05 10:02
Analysts’ Top Healthcare Picks: Avidity Biosciences (RNA), Irhythm Technologies (IRTC)
Avidity Biosciences, Irhythm Technologies and BridgeBio Pharma have 3 analysts with bullish sentiments on the Healthcare sector. 3 analysts have assigned Buy ratings to the 3 stocks. Avidity B biosciences has a price target of $50.00; Irh Rhythm Technologies has a $135.00 price target.
TipRanks · 03/05 10:01
U.S. RESEARCH ROUNDUP-Bark, Fleetcor Technologies, Tesla
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Bark, Fleetcor Technologies and Tesla are among the companies. The analysts raised their ratings on Bark and raised their targets for Fleetcor and Tesla. The companies are all listed on the New York Stock Exchange.
Reuters · 03/05 06:57
Buy Rating Affirmed for Avidity Biosciences Following Promising MARINA-OLE Study Data and RNA Analysis
TipRanks · 03/05 02:36
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Bitdeer Technologies Group shares jumped 10.2% to $7.45 on Monday. The company announced successful testing of its SEAL01 Bitcoin mining chip. BitFuFu Inc. Shares jumped 107% in the mid-day session. Macy's, Inc. And MGE also rose amid strength in the price of Bitcoin.
Benzinga · 03/04 18:29
More
Webull provides a variety of real-time RNA stock news. You can receive the latest news about Avidity Biosciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RNA
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.